Let's Talk Alzheimer's

Could bacteria linked to gum disease play a role in Alzheimer’s disease? Emerging science suggests that P. gingivalis, a bacterium associated with gum disease, may contribute to inflammation and brain damage linked to Alzheimer’s disease. In this episode, Dr. Michael J. Detke of Lighthouse Pharma discusses the SPRING clinical trial and the investigational oral drug LHP588, which is being studied a...

Exciting advances in understanding Alzheimer’s biology, genetics, and biomarkers are driving new medicines, devices, and prevention strategies. In 2025 alone, 182 clinical trials evaluated 138 novel drugs for Alzheimer’s disease. In this episode, leading expert Dr. Jeffrey Cummings from the University of Nevada Las Vegas shares an insider’s look at the rapidly evolving Alzheimer’s treatment pipeli...

Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, shares insights from the groundbreaking U.S. POINTER trial—the largest study of its kind exploring how lifestyle changes impact brain health. She breaks down how factors like exercise, nutrition, cognitive engagement, and social connection work together, and what prac...

Detecting subtle changes in memory or thinking can be unsettling, but understanding what’s behind those changes can lead to critical early diagnosis—or even rule out Alzheimer’s altogether. In this episode, behavioral neurologist Dr. Sharon Cohen, medical director at Toronto Memory Program, explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, an...

Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. Dr. Armen J. Moughamian, a neurologist and medical director of the Ray Dolby Brain Healt...